Ang, Wee HanGrote, ZachariasScopelliti, RosarioJuillerat-Jeanneret, LucienneSeverin, KayDyson, Paul J.2009-09-242009-09-24200910.1016/j.jorganchem.2008.11.026https://infoscience.epfl.ch/handle/20.500.14299/42913WOS:000264064900026Organometallic half-sandwich complexes based on ruthenium with aminomethyl-substituted 3-hydroxy-2-pyridone ligands exist in aqueous solution as monomeric O,O′-chelate complexes or trimeric metallamacrocycles depending upon the pH. We hypothesized that administration of the compounds as stable trimers, which subsequently convert to active monomers at the reduced pH of the cancer environment, could facilitate their delivery to cancer cells without undergoing deactivation. Thus, the compounds were evaluated against cancer and fibroblast cell lines in vitro. A series of rhodium complexes, which exist mainly as monomers at neutral pH, were also studied for comparative purposes.BioorganometallicAnticancer drugsMedicinal chemistryX-ray crystallographyRutheniumRhodiumVitro Anticancer ActivityIron-Deficiency AnemiaIn-VitroMetal-ComplexesRuthenium ComplexesArene ComplexesAntitumor DrugsPta ComplexesWaterChemistryOrganometallic complexes that interconvert between trimeric and monomeric structures as a function of pH and their effect on human cancer and fibroblast cellstext::journal::journal article::research article